EP4698197A1 - ANTIBIOTIQUE ET MICRO-ORGANISME AYANT UNE ACTIVITÉ DE DÉSHYDROXYLATION DE L'ACIDE BILIAIRE 7a POUR LE TRAITEMENT DE MALADIES NON INFECTIEUSES - Google Patents

ANTIBIOTIQUE ET MICRO-ORGANISME AYANT UNE ACTIVITÉ DE DÉSHYDROXYLATION DE L'ACIDE BILIAIRE 7a POUR LE TRAITEMENT DE MALADIES NON INFECTIEUSES

Info

Publication number
EP4698197A1
EP4698197A1 EP24720482.9A EP24720482A EP4698197A1 EP 4698197 A1 EP4698197 A1 EP 4698197A1 EP 24720482 A EP24720482 A EP 24720482A EP 4698197 A1 EP4698197 A1 EP 4698197A1
Authority
EP
European Patent Office
Prior art keywords
microorganism
antibiotic
gut
days
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24720482.9A
Other languages
German (de)
English (en)
Inventor
Kristina SCHOONJANS
Alessia PERINO
Antoine JALIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecole Polytechnique Federale de Lausanne EPFL
Original Assignee
Ecole Polytechnique Federale de Lausanne EPFL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Polytechnique Federale de Lausanne EPFL filed Critical Ecole Polytechnique Federale de Lausanne EPFL
Publication of EP4698197A1 publication Critical patent/EP4698197A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un ou plusieurs antibiotiques qui perturbent l'équilibre microbien de l'intestin et un micro-organisme ayant une activité de déshydroxylation de l'acide biliaire 7α pour une utilisation dans le traitement d'une maladie non infectieuse chez un sujet.
EP24720482.9A 2023-04-20 2024-04-18 ANTIBIOTIQUE ET MICRO-ORGANISME AYANT UNE ACTIVITÉ DE DÉSHYDROXYLATION DE L'ACIDE BILIAIRE 7a POUR LE TRAITEMENT DE MALADIES NON INFECTIEUSES Pending EP4698197A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23168848 2023-04-20
PCT/EP2024/060482 WO2024218184A1 (fr) 2023-04-20 2024-04-18 ANTIBIOTIQUE ET MICRO-ORGANISME AYANT UNE ACTIVITÉ DE DÉSHYDROXYLATION DE L'ACIDE BILIAIRE 7α POUR LE TRAITEMENT DE MALADIES NON INFECTIEUSES

Publications (1)

Publication Number Publication Date
EP4698197A1 true EP4698197A1 (fr) 2026-02-25

Family

ID=86096069

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24720482.9A Pending EP4698197A1 (fr) 2023-04-20 2024-04-18 ANTIBIOTIQUE ET MICRO-ORGANISME AYANT UNE ACTIVITÉ DE DÉSHYDROXYLATION DE L'ACIDE BILIAIRE 7a POUR LE TRAITEMENT DE MALADIES NON INFECTIEUSES

Country Status (2)

Country Link
EP (1) EP4698197A1 (fr)
WO (1) WO2024218184A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119265085B (zh) * 2024-12-06 2025-04-29 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一株能改善代谢相关脂肪性肝炎的普拉梭菌及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4527400A3 (fr) 2014-05-19 2025-06-11 Memorial Sloan Kettering Cancer Center Procédés et compositions pour réduire une infection par clostridium difficile
GB201806105D0 (en) * 2018-04-13 2018-05-30 Imperial Innovations Ltd Clostridioides difficile
JP7558170B2 (ja) * 2018-08-17 2024-09-30 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法
US12501917B2 (en) * 2019-01-23 2025-12-23 Mars, Incorporated Methods and compositions for treating intestinal disorder

Also Published As

Publication number Publication date
WO2024218184A1 (fr) 2024-10-24

Similar Documents

Publication Publication Date Title
Zhao et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome
Wu et al. Akkermansia muciniphila alleviates high‐fat‐diet‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids
Spivak et al. Local and systemic effects of microbiome‐derived metabolites
Lee et al. A novel bacterium, Butyricimonas virosa, preventing HFD-induced diabetes and metabolic disorders in mice via GLP-1 receptor
Laurans et al. Genetic deficiency of indoleamine 2, 3-dioxygenase promotes gut microbiota-mediated metabolic health
Liang et al. Lactiplantibacillus plantarum H-87 prevents high-fat diet-induced obesity by regulating bile acid metabolism in C57BL/6J mice
Miazga et al. Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO
Li et al. l-Arabinose inhibits colitis by modulating gut microbiota in mice
Chen et al. Glucocorticoid-induced loss of beneficial gut bacterial extracellular vesicles is associated with the pathogenesis of osteonecrosis
Ke et al. Fucose ameliorate intestinal inflammation through modulating the crosstalk between bile acids and gut microbiota in a chronic colitis murine model
Vianello et al. Epicardial adipocyte hypertrophy: association with M1-polarization and toll-like receptor pathways in coronary artery disease patients
Luo et al. Microbial DNA enrichment promotes liver steatosis and fibrosis in the course of non‐alcoholic steatohepatitis
Jiang et al. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development
Haub et al. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice
Bellin et al. Total pancreatectomy with islet autotransplantation: summary of a National Institute of Diabetes and Digestive and Kidney diseases workshop
Hou et al. Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review
Hathaway‐Schrader et al. Specific commensal bacterium critically regulates gut microbiota osteoimmunomodulatory actions during normal postpubertal skeletal growth and maturation
Zheng et al. Oral propolis nanoemulsions modulate gut microbiota to balance bone remodeling for enhanced osteoporosis therapy
Wu et al. Washed microbiota transplantation improves patients with high blood glucose in South China
Naimi et al. Effects of glepaglutide, a long‐acting glucagon‐like peptide‐2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial
Jahn et al. Non-alcoholic steatohepatitis: from pathophysiology to novel therapies
WO2019075344A1 (fr) Transplantation de microbiote fécal pour traiter la rectocolite hémorragique
Ju et al. Helicobacter pylori and alzheimer’s disease-related metabolic dysfunction: Activation of TLR4/myd88 inflammation pathway from p53 perspective and a case study of low-dose radiation intervention
Guo et al. Paneth Cell Ablation Aggravates Pancreatic and Intestinal Injuries in a Rat Model of Acute Necrotizing Pancreatitis after Normal and High‐Fat Diet
WO2024218184A1 (fr) ANTIBIOTIQUE ET MICRO-ORGANISME AYANT UNE ACTIVITÉ DE DÉSHYDROXYLATION DE L'ACIDE BILIAIRE 7α POUR LE TRAITEMENT DE MALADIES NON INFECTIEUSES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR